Evidence map›Paper›PMID 34400666›Full record

ArticleScientific reports2021

Comparative analysis of machine learning approaches to classify tumor mutation burden in lung adenocarcinoma using histopathology images.

Apaar Sadhwani, Huang-Wei Chang, Ali Behrooz, Trissia Brown, Isabelle Auvigne-Flament, Hardik Patel, Robert Findlater, Vanessa Velez, Fraser Tan, Kamilla Tekiela and 9 more

Abstract readComparative Study
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Apaar Sadhwani *Google Health, Palo Alto, CA, USA.
Huang-Wei Chang *Verily Life Sciences, South San Francisco, CA, USA.
Ali BehroozVerily Life Sciences, South San Francisco, CA, USA.
Trissia BrownGoogle Health via Vituity, Emeryville, CA, USA.
Isabelle Auvigne-FlamentGoogle Health via Vituity, Emeryville, CA, USA.
Hardik PatelVerily Life Sciences, South San Francisco, CA, USA.
Robert FindlaterVerily Life Sciences, South San Francisco, CA, USA.
Vanessa VelezVerily Life Sciences, South San Francisco, CA, USA.
Fraser TanGoogle Health, Palo Alto, CA, USA.
Kamilla TekielaVerily Life Sciences, South San Francisco, CA, USA.
Ellery WulczynGoogle Health, Palo Alto, CA, USA.
Eunhee S YiDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Craig H MermelGoogle Health, Palo Alto, CA, USA.
Debra HanksVerily Life Sciences, South San Francisco, CA, USA.
Po-Hsuan Cameron ChenGoogle Health, Palo Alto, CA, USA.
Kimary KuligVerily Life Sciences, South San Francisco, CA, USA.
Cory BatenchukVerily Life Sciences, South San Francisco, CA, USA.
David F SteinerGoogle Health, Palo Alto, CA, USA. davesteiner@google.com.
Peter CimermancicVerily Life Sciences, South San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Both histologic subtypes and tumor mutation burden (TMB) represent important biomarkers in lung cancer, with implications for patient prognosis and treatment decisions. Typically, TMB is evaluated by comprehensive genomic profiling but this requires use of finite tissue specimens and costly, time-consuming laboratory processes. Histologic subtype classification represents an established component of lung adenocarcinoma histopathology, but can be challenging and is associated with substantial inter-pathologist variability. Here we developed a deep learning system to both classify histologic patterns in lung adenocarcinoma and predict TMB status using de-identified Hematoxylin and Eosin (H&E) stained whole slide images. We first trained a convolutional neural network to map histologic features across whole slide images of lung cancer resection specimens. On evaluation using an external data source, this model achieved patch-level area under the receiver operating characteristic curve (AUC) of 0.78-0.98 across nine histologic features. We then integrated the output of this model with clinico-demographic data to develop an interpretable model for TMB classification. The resulting end-to-end system was evaluated on 172 held out cases from TCGA, achieving an AUC of 0.71 (95% CI 0.63-0.80). The benefit of using histologic features in predicting TMB is highlighted by the significant improvement this approach offers over using the clinical features alone (AUC of 0.63 [95% CI 0.53-0.72], p = 0.002). Furthermore, we found that our histologic subtype-based approach achieved performance similar to that of a weakly supervised approach (AUC of 0.72 [95% CI 0.64-0.80]). Together these results underscore that incorporating histologic patterns in biomarker prediction for lung cancer provides informative signals, and that interpretable approaches utilizing these patterns perform comparably with less interpretable, weakly supervised approaches.

Indexed as

Deep LearningMutationAdenocarcinoma of LungAdultAgedAged, 80 and overAge FactorsArea Under CurveCarcinoma, Non-Small-Cell LungColoring AgentsDatasets as TopicEosine Yellowish-(YS)FemaleHematoxylinHumansLung NeoplasmsColoring AgentsEosine Yellowish-(YS)Hematoxylin

Identifiers

PMID34400666
PMCPMC8368039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.